These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 31207314)

  • 1. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer.
    Xiong Y; Wang Y; Tiruthani K
    Nanomedicine; 2019 Oct; 21():102034. PubMed ID: 31207314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
    Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
    Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy.
    Abdelgalil RM; Elmorshedy YM; Elkhodairy KA; Teleb M; Bekhit AA; Khattab SN; Elzoghby AO
    Nanomedicine (Lond); 2022 Sep; 17(22):1721-1745. PubMed ID: 36621872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies.
    Han YJ; Shao CY; Yao Y; Zhang Z; Fang MZ; Gong T; Zhang YJ; Li M
    Postgrad Med J; 2024 May; 100(1184):373-381. PubMed ID: 38211949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Expanding Role for Immunotherapy in Colorectal Cancer.
    Bever KM; Le DT
    J Natl Compr Canc Netw; 2017 Mar; 15(3):401-410. PubMed ID: 28275038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
    Link JT; Overman MJ
    Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The colorectal cancer immune microenvironment and approach to immunotherapies.
    Koi M; Carethers JM
    Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell-based immunotherapy in colorectal cancer.
    Feng M; Zhao Z; Yang M; Ji J; Zhu D
    Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Colorectal Cancer - Finding the Achilles' Heel.
    Park R; Saeed A
    NEJM Evid; 2024 Jun; 3(6):EVIDra2300353. PubMed ID: 38804784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on colorectal cancer microenvironment, epigenetic and immunotherapy.
    Jin K; Ren C; Liu Y; Lan H; Wang Z
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107041. PubMed ID: 33045561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
    Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
    Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Modeling the Immune Microenvironment of Colorectal Cancer.
    Yoon PS; Del Piccolo N; Shirure VS; Peng Y; Kirane A; Canter RJ; Fields RC; George SC; Gholami S
    Front Immunol; 2020; 11():614300. PubMed ID: 33643296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies.
    Zhang Y; Xu J; Zhang N; Chen M; Wang H; Zhu D
    Cancer Lett; 2019 Aug; 458():123-135. PubMed ID: 31121212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.
    Kamal Y; Schmit SL; Frost HR; Amos CI
    Immunotherapy; 2020 Oct; 12(14):1083-1100. PubMed ID: 32787587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
    Chen Y; Zheng X; Wu C
    Front Immunol; 2021; 12():792691. PubMed ID: 34925375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment.
    Bai J; Chen H; Bai X
    J Clin Lab Anal; 2021 Jun; 35(6):e23810. PubMed ID: 33938589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.